Skip to main content

Table 3 Some approved COVID-19 vaccines with their developer, origin, type, dosage and storage conditions

From: Current challenges in different approaches to control COVID-19: a comprehensive review

Name of the vaccine Developer Developer country Vaccine type No. of doses Efficacy (%) Storage (°C) References
BNT162b2 (Comirnaty) Pfizer-BioNtech USA and Germany mRNA IM (2) 95 − 80 to – 60 Polack et al. (2020)
mRNA-1273 (Moderna COVID-19 Vaccine) Moderna USA mRNA IM (2) 94.0 − 25 to − 15 Baden et al. (2021)
Ad26.COV2.S (Janssen COVID-19 vaccine) Janssen Pharmaceuticals USA and Germany Viral vector IM 1 81.7 2–8 Sadoff et al. (2021)
ChAdOx1 nCoV-19 (AZD-1222) (Covishield) Oxford-AstraZeneca UK, Sweden and India Viral vector IM (2) 81 2–8 Voysey et al. (2021)
Sputnik V Gamaleya Research Institute Russia Viral vector IM (2) 91.6 2–8 Logunov et al. (2021)
BBV152 (Covaxin) Bharat Biotech India Inactivated IM (2) 78 2–8 Ella et al. (2021)
CronaVac Sinovac China Inactivated IM (2) 50.4 2–8 Zhang et al. (2021)
BBIBP-CorV Sinopharm China Inactivated IM (2) 79.3 2–8 Xia et al. (2021)
NVX-CoV2373 Novavax USA Protein subunit IM (2) 96 2–8 Shinde et al. (2021)
CVnCoV CureVac Germany mRNA IM (2) 48.2 2–8 Hadj Hassine (2021)
AD5-nCOV (Convidecia) CanSino Biologics China Viral vector IM, IN (1) 63 2–8 Wu et al. (2021)
SCB-2019 Clover Biopharmaceu ticals China Protein subunit IM 67 2–8 Bravo et al. (2022)
ZyCoV-D Cadila Healthcare India DNA plasmid ID (3) 66.6 2–8 Chavda et al. (2021)
ZF2001 (Zifivax) Anhui Zhifei Longcom China Protein subunit IM (3) 82 2–8 Yang et al. (2021)
  1. IM intramuscular, IN intranasal, ID intradermal